The Japanese Journal of Antibiotics
Online ISSN : 2186-5477
Print ISSN : 0368-2781
ISSN-L : 0368-2781
Volume 72, Issue 4
Displaying 1-3 of 3 articles from this issue
Original Article
Research Report
  • Hiroki Namikawa, Ken-Ichi Oinuma, Yukihiro Kaneko, Hiroshi Kakeya
    2019 Volume 72 Issue 4 Pages 301-306
    Published: December 25, 2019
    Released on J-STAGE: June 20, 2024

    In recent years, the increase in the incidence of hypermucoviscous Klebsiella pneumoniae (hvKP) infections has become a clinical concern worldwide. The high pathogenicity of hvKP is in part attributed to the overproduction of capsular polysaccharide (CPS), which is achieved by the action of a positive regulator of capsular polysaccharide synthesis genes, named rmpA. There have been many studies on the mechanism of hvKP virulence, but no study has focused on the development of anti-virulence therapies. We tried to identify antimicrobial drugs that can suppress the hypermucoviscosity of hvKP. As a result, we found that rifampicin (RFP) has a strong anti-mucoviscous activity against hvKP. RFP treatment caused a drastic reduction in the thickness of the CPS layer around hvKP cells and suppressed transcript levels of capsule-related genes including rmpA. Our data suggest that RFP may be useful as a potential anti-virulence agent for intractable infections caused by hvKP.

    Download PDF (509K)
Reference Materials